<DOC>
	<DOCNO>NCT00324740</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose isotretinoin give together vorinostat see well work treat patient advanced kidney cancer . Vorinostat may stop growth tumor cell block enzymes need cell growth . Isotretinoin may cause kidney cancer cell look like normal cell , grow spread slowly . Giving vorinostat together isotretinoin may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat Isotretinoin Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose phase II dose isotretinoin give combination vorinostat ( SAHA ) patient advance renal cell carcinoma . ( Phase I ) II . Define dose-limiting toxicity patient treat regimen . ( Phase I ) III . Determine objective response rate patient treat regimen . ( Phase II ) SECONDARY OBJECTIVES : I . Conduct pharmacokinetic analysis regimen patient . ( Phase I ) II . Conduct gene profile analysis pre-study , paraffin-embedded tissue patient treat regimen . ( Phase I ) III . Conduct correlative study identify effect SAHA isotretinoin RAR-B , LRAT , STAT1-3 expression . ( Phase I ) OUTLINE : This multicenter , phase I , dose-escalation study isotretinoin , follow multicenter , phase II , prospective , non-randomized study . Phase I : Patients receive oral vorinostat ( SAHA ) twice daily oral isotretinoin twice daily day 3-5 , 10-12 , 17-19 , 24-26 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos isotretinoin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Phase II : Patients receive SAHA phase I isotretinoin phase I MTD determine phase I. Tissue blood sample obtain biomarker/laboratory study week 1 4 . Gene profile analysis conduct tumor tissue . After completion study treatment , patient follow 12 week .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Histologically cytologically confirm renal cell carcinoma Advanced metastatic disease Measurable disease , define ≥ 1 unidimensionally measurable lesion &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan ( phase II ) Failed ≥ 2 prior treatment regimen , include chemotherapy , immunotherapy ( i.e. , interleukin interferon ) , biological agent ( i.e. , kinase inhibitor ) , combination thereof An overlap class therapy give concurrently count 2 prior treatment regimens No known brain metastasis ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 3 month WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT &lt; 2.5 time upper limit normal Creatinine ≤ 2 mg/dL OR creatinine clearance &gt; 50 mL/min Negative pregnancy test Exclusion criterion : Not pregnant nursing No history allergic reaction hypersensitivity attribute compound similar chemical biologic composition vorinostat ( SAHA ) , isotretinoin , agent component ( e.g. , parabens ) use study No uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No concurrent antiretroviral therapy HIVpositive patient No concurrent anticancer therapy , include radiation , biologic , chemotherapeutic agent , renal cell carcinoma tumors No concurrent investigational agent , valproic acid , retinoid</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>